Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu, Jesse M. Zaretsky, Siwen Hu‐Lieskovan, et al.
Nature (2018) Vol. 553, Iss. 7688, pp. 347-350
Open Access | Times Cited: 302

Showing 1-25 of 302 citing articles:

Cancer immunotherapy using checkpoint blockade
Antoni Ribas, Jedd D. Wolchok
Science (2018) Vol. 359, Iss. 6382, pp. 1350-1355
Open Access | Times Cited: 5323
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jérôme Galon, Daniela Bruni
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 3, pp. 197-218
Closed Access | Times Cited: 2614
Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde, Daniel S. Chen
Immunity (2020) Vol. 52, Iss. 1, pp. 17-35
Open Access | Times Cited: 1604
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 5, pp. 325-340
Open Access | Times Cited: 1538
Tertiary lymphoid structures in the era of cancer immunotherapy
Catheriné Sautès-Fridman, Florent Petitprez, Julien Caldéraro, et al.
Nature reviews. Cancer (2019) Vol. 19, Iss. 6, pp. 307-325
Open Access | Times Cited: 1299
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Caroline S. Jansen, Nataliya Prokhnevska, Viraj A. Master, et al.
Nature (2019) Vol. 576, Iss. 7787, pp. 465-470
Open Access | Times Cited: 650
The hallmarks of successful anticancer immunotherapy
Lorenzo Galluzzi, Timothy A. Chan, Guido Kroemer, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 459
Open Access | Times Cited: 491
Application of PD-1 Blockade in Cancer Immunotherapy
Xiaomo Wu, Zhongkai Gu, Chen Yang, et al.
Computational and Structural Biotechnology Journal (2019) Vol. 17, pp. 661-674
Open Access | Times Cited: 433
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
John D. Martin, Giorgio Seano, Rakesh K. Jain
Annual Review of Physiology (2019) Vol. 81, Iss. 1, pp. 505-534
Open Access | Times Cited: 406
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser, Leonid Cherkassky, Navin K. Chintala, et al.
Cancer Cell (2019) Vol. 36, Iss. 5, pp. 471-482
Open Access | Times Cited: 405
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 403
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
F. Wang, Xiaoli Wei, Fenggong Wang, et al.
Annals of Oncology (2019) Vol. 30, Iss. 9, pp. 1479-1486
Open Access | Times Cited: 380
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
David E. Elder, Boris C. Bastian, Ian A. Cree, et al.
Archives of Pathology & Laboratory Medicine (2020) Vol. 144, Iss. 4, pp. 500-522
Open Access | Times Cited: 367
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tianyu Tang, Xing Huang, Gang Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 345
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Imanol Arozarena, Claudia Wellbrock
Nature reviews. Cancer (2019) Vol. 19, Iss. 7, pp. 377-391
Open Access | Times Cited: 325
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Samuel J. Klempner, David Fabrizio, Shalmali Bane, et al.
The Oncologist (2019) Vol. 25, Iss. 1, pp. e147-e159
Open Access | Times Cited: 311
Cutaneous melanoma
Georgina V. Long, Susan M. Swetter, Alexander M. Menzies, et al.
The Lancet (2023) Vol. 402, Iss. 10400, pp. 485-502
Closed Access | Times Cited: 311
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Christopher Nevala-Plagemann, Manuel Hidalgo, Ignacio Garrido‐Laguna
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 2, pp. 108-123
Closed Access | Times Cited: 307
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Anliang Xia, Yan Zhang, Xu Jiang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 289
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 282
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
Vivek Verma, Rajeev Shrimali, Shamim Ahmad, et al.
Nature Immunology (2019) Vol. 20, Iss. 9, pp. 1231-1243
Open Access | Times Cited: 263
Immunotherapy of Melanoma: Facts and Hopes
Sarah A. Weiss, Jedd D. Wolchok, Mario Sznol
Clinical Cancer Research (2019) Vol. 25, Iss. 17, pp. 5191-5201
Open Access | Times Cited: 236
Host tissue determinants of tumour immunity
Hélène Salmon, Romain Remark, Sacha Gnjatic, et al.
Nature reviews. Cancer (2019)
Open Access | Times Cited: 226
Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment
Alba Nicolás‐Boluda, Javier Vaquero, Lene Vimeux, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 213
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
Marcin Kowanetz, Wei Zou, Scott Gettinger, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 43
Open Access | Times Cited: 203
Page 1 - Next Page

Scroll to top